351 results on '"Casanovas, Oriol"'
Search Results
2. Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trial
3. Oxygen matters: Unraveling the role of oxygen in the neuronal response to cisplatin.
4. Gemelo digital de una viga biapoyada para la monitorización del daño a fatiga
5. Mechanisms of Anti-angiogenic Therapy
6. Mechanisms of Tumor Angiogenesis
7. EDITORIAL : EN EL CENTENARIO DEL TRATADO DE VERSALLES
8. Kidney cancer PDOXs reveal patient‐specific pro‐malignant effects of antiangiogenics and its molecular traits
9. Angiogenesis and Metabolism: Entwined for Therapy Resistance
10. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence
11. LOS PRINCIPIOS DE IGUALDAD SOBERANA Y NO INTERVENCIÓN FRENTE A LA HEGEMONÍA EN EL ORDEN INTERNACIONAL
12. Data from A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination
13. Supplementary Figures 1-12 from A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination
14. Supplementary Figure Legends from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
15. Supplementary Figure 3 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
16. Supplementary Methods from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
17. Supplementary Figure 2 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
18. Supplementary Figure 4 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
19. Data from Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents
20. Supplementary Figure 5 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
21. Data from Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors
22. Figure S2 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
23. Supplementary Table 1 from Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents
24. Supplementary Figure 6 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
25. Supplementary Materials and Methods from Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents
26. Supplementary Table 3 from Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents
27. Supplementary Data from Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors
28. Supplementary Figures 1-14 from Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents
29. Supplementary Table S2 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
30. Supplementary Data Index from Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents
31. Supplementary Figure 1 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
32. Supplementary Table 2 from Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents
33. Data from Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization
34. Supplementary Methods from Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization
35. Supplementary Figure Legends 1-9 from Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization
36. Supplementary Figures 1-9 from Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization
37. Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours:findings from the phase II TALENT trial
38. Relevance of Angiogenesis in Neuroendocrine Tumors
39. Promalignant effects of antiangiogenics in the tumor microenvironment
40. Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility
41. SETENTA Y CINCO AÑOS DE DERECHO INTERNACIONAL PÚBLICO EN LA REVISTA ESPAÑOLA DE DERECHO INTERNACIONAL.
42. Mechanisms of Anti-Angiogenic Therapy
43. Mechanisms of Anti-Angiogenic Therapy
44. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing
45. Mechanisms of Tumor Angiogenesis
46. Contrasting responses of non‐small cell lung cancer to antiangiogenic therapies depend on histological subtype
47. PATIENT-DERIVED AVATAR MOUSE MODELS PREDICTS PROGNOSIS IN ADVANCED RENAL CELL CARCINOMA.: MP71-20
48. Filamin B Plays a Key Role in Vascular Endothelial Growth Factor-induced Endothelial Cell Motility through Its Interaction with Rac-1 and Vav-2
49. HighFGFR1–4mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
50. A novel role for an RCAN3-derived peptide as a tumor suppressor in breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.